[Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma].
- DOI
- 10.3760/cma.j.cn121090-20260226-00109
- Published
- 2026 Jul 14
- Container
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3760/cma.j.cn121090-20260226-00109,
title = {[Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma].},
author = {Mi XR and Xiong WJ and Yan YT and Wang TY and An G and Zou DH and Xu Y and Liu W and Qiu LG and Lyu R and Yi SH},
year = {2026},
journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
doi = {10.3760/cma.j.cn121090-20260226-00109},
url = {https://doi.org/10.3760/cma.j.cn121090-20260226-00109}
}RIS
TY - JOUR TI - [Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma]. AU - Mi XR AU - Xiong WJ AU - Yan YT AU - Wang TY AU - An G AU - Zou DH AU - Xu Y AU - Liu W AU - Qiu LG AU - Lyu R AU - Yi SH PY - 2026 JO - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi DO - 10.3760/cma.j.cn121090-20260226-00109 UR - https://doi.org/10.3760/cma.j.cn121090-20260226-00109 ER -
APA
XR, M., WJ, X., YT, Y., TY, W., G, A., DH, Z., Y, X., W, L., LG, Q., R, L., & SH, Y. (2026). [Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. https://doi.org/10.3760/cma.j.cn121090-20260226-00109
Source records
- pubmed · retrieved 2026-09-26T20:08:57.619Z